Blog
News &
Updates
Revital Healthcare banks blanket contract
from a key global organisation
Revital Healthcare has recently secured a notable contract with a global organization to supply India with 50 million units of 2ML vaccine syringes amidst concerns over a shortage of this precious commodity. Following a highly competitive bidding process, Revital emerged as the winning candidate for the tender valued at Sh150 million, beating out several other leading manufacturers. This recent development has made the company Africa’s largest medical device manufacturer.
The pressing shortage of various types of syringes has led Revital Healthcare to offer the 0.5ML Auto-Disable Syringe as a viable alternative solution for vaccination purposes on a global scale. The Kenyan-based medical supply manufacturer is well-equipped to meet this challenge, as it produces both two-part and three-part 2ml syringes, for which it has received contracts for both.
Furthermore, several major organizations have shown their confidence in Revital by awarding the firm a blanket contract for the entire year of 2022, reserving 100% of the 0.5ml syringes produced. As a leading local manufacturer, Revital has consistently expressed its readiness to assist the government in its efforts to combat the ongoing global pandemic.
Speaking to a Kenya news agency, Ronnek Vora, Revital’s Sales and Marketing Director, emphasized that this a win for Kenya as well.

They have identified the 2ml because of the low dead space on the syringe so they can utilize the entire vial for the dosage of the patients. We continually ask for the government’s support because by supporting us, they are supporting the 500 people working in this factory. This is a plus for Kenya as a country and President Uhuru’s legacy of Buy Kenya, Build Kenya,
Roneek Vora,
Sales, Marketing & Development Director at Revital Healthcare
As of 2013, Revital Healthcare has been consistently producing an average of 74 million syringes yearly. However, given the current upsurge in global demand for vaccine syringes, the firm will be compelled to triple its production output to approximately 320 million syringes annually. This growth trajectory will necessitate the hiring of more personnel, and the company has already declared that it will be recruiting at least 100 new employees to cater to the augmented demand.


“We are planning to increase production further by another 100 -150 million by the following year. As per our promise to the foundation, we are going to re-invest our funds from these products to expand our product range. This will create more than 5,000 other jobs indirectly,
Roneek Vora,
Sales, Marketing & Development Director at Revital Healthcare
Ronnek Vora further stated that Revital aims to reduce this major gap as fast as possible. Meanwhile, Revital Healthcare has been actively advocating for governments worldwide to place equal emphasis on syringes as they do on vaccines.

With this deficit of up to 4 billion syringes, we want to reduce this gap as much as possible because most of the vaccine syringes will be coming to Africa. Since March last year, we have been telling the world they are focusing too much on vaccines but no one is looking at syringes and that there is going to be a shortfall for this product. Today, we are witnessing the shortfall.
Roneek Vora,
Sales, Marketing & Development Director at Revital Healthcare
More From This Category
Revital Featured on The Star: A Journey of Hope, Growth, and Purpose
FeaturedRevital Featured on The Star: A Journey of Hope, Growth, and PurposeFeatured in The Star for its inspiring journey from a small syringe manufacturer in Kilifi to one of Africa’s largest medical device manufacturers. Highlighting our founder Rajni Vora’s vision...
Revital–Corning Partnership to Boost African Healthcare
Strategic AllianceRevital–Corning Partnership to Boost African HealthcareRevital Healthcare has partnered with global science leader Corning to establish a life sciences manufacturing hub in Africa. This groundbreaking collaboration aims to localize production of...
A New Chapter Begins: Navin Choubey Appointed CEO of Revital Healthcare
AnnouncementA New Chapter Begins: Navin Choubey Appointed CEO of Revital HealthcareRevital Healthcare proudly announces Navin Choubey as CEO, marking a bold new chapter in African healthcare manufacturing. With visionary leadership, we’re expanding globally,...
Revital Healthcare to Export 50 Million COVID-19 Syringes to India
BusinessRevital Healthcare to Export 50 Million COVID-19 Syringes to IndiaRevital Healthcare has secured a KES 150 million contract with UNICEF India to supply 50 million COVID-19 syringes, marking Kenya’s first syringe export to India and strengthening Africa’s role...
Revital Healthcare Secures Historic Syringe Export Deal with Pakistan
BusinessRevital Healthcare Secures Historic Syringe Export Deal with PakistanRevital Healthcare has signed a groundbreaking two-year syringe export deal with Pakistan, marking a major milestone in African manufacturing and expanding Kenya’s role in global healthcare...
Advancing Local Medical Device Manufacturing in Africa
FeaturedAdvancing Local Medical Device Manufacturing in AfricaRevital Healthcare is transforming Africa’s health sector by locally manufacturing essential medical devices, including WHO-prequalified auto-disable syringes. Supporting Africa CDC’s vision, Revital plays...







